Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.
BACKGROUND
During the recovery period after anticancer myelosuppressive therapy, hematopoietic progenitor cells become mitotically active in order to replenish the bone marrow compartment and remain hyperproliferative even after normalization of peripheral white blood cells and platelets. At this stage, the progenitors are more radiosensitive and chemosensitive. Dosing patients with additional cytotoxic therapy during this phase will likely result in more severe toxicity. For example, the authors have noted that the red bone marrow (RM) dose resulting from radioantibody therapy does not correlate with observed bone marrow toxicity. Several patients given similar RM doses had Grade 3 or 4 toxicity, whereas others had Grade 0-2 toxicity even though their white blood cell (WBC) and (PLT) counts were normal at the time of dosing. The goal of these studies was to establish a noninvasive predictive marker of bone marrow activity that could determine stem cell and progenitor cell recovery from previous myelosuppressive therapy.


METHODS
A retrospective study was conducted to quantitate plasma levels of 5 cytokines regulating hematopoiesis, namely, 2 stimulatory fms-like tyrosine kinase (FLT3-L) and stem cell factor (SCF) and 3 inhibitory growth factors tumor necrosis factor-alpha (TNFalpha), tumor growth factor-beta, and macrophage inflammatory protein (MIP-1alpha), by immunoassay in 43 patients enrolled in clinical trials at Garden State Cancer Center in Belleville, New Jersey. All patients had had previous chemotherapy with a duration of 1-24 months. The serum cytokine values were correlated with the magnitude of leukopenia or thrombocytopenia following a single dose of radioantibody as the cytotoxic therapy.


RESULTS
Plasma FLT3-L levels predicted excess platelet toxicity in 13 of 16 patients (mean = 225 +/- 106 pg/mL) and resulted in a false-positive in only 3 of 27 other patients (mean = 80 +/- 41 pg/mL). Plasma FLT3-L > 135 pg/mL resulted in 81% sensitivity and 89% and 86% specificity and accuracy, respectively, for predicting excess toxicity caused by additional cytotoxic therapy. The positive likelihood ratio was 7.5 (95% confidence interval, 2.5-22.5) and the negative likelihood ratio was 0.19 (95% confidence interval, 0.05-0.67).


CONCLUSIONS
Elevated plasma FLT3-L in patients who previously received chemotherapy is a predictive measure of the stage of recovery of the bone marrow compartment. FLT3-L seems to identify the likelihood that the patient will experience Grade > or = 3 thrombocytopenia if additional cytotoxic therapy is administered. Knowledge of bone marrow activity should permit therapy that is more aggressive by establishing the earliest possible time for dosing with any cytotoxic agent for which myelosuppression is the dose-limiting toxicity.
Blumenthal
R D
RD
Garden State Cancer Center, Belleville, New Jersey 07109, USA.
Lew
W
W
Juweid
M
M
Alisauskas
R
R
Ying
Z
Z
Goldenberg
D M
DM
D000970:Antineoplastic Agents / Q000009:adverse effects; D001854:Bone Marrow Cells / Q000502:physiology*; D016207:Cytokines / Q000032:analysis*; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000502:physiology*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced*; D011237:Predictive Value of Tests; D011518:Proto-Oncogene Proteins / Q000097:blood*; D020794:Receptor Protein-Tyrosine Kinases / Q000097:blood*; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced*; D051941:fms-Like Tyrosine Kinase 3
D000970:Antineoplastic Agents; D016207:Cytokines; D011518:Proto-Oncogene Proteins; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3